Primary Hypertension Clinical Trial
Official title:
Effect of Aerobic EXercise on MiCroVAscular RarefacTION in Chinese Mild HyperteNsive Patients(EXCAVATION-CHN1)
The purpose of this study is to determine the effect of aerobic exercise training on microcirculation rarefaction in Chinese young male primary hypertensive patients stage 1. Hypertension is one of the most common world-wide chronic diseases, and it is showing a growing younger trend, which with mild blood pressure elevated would not be diagnose in time until blood pressure raises up or symptoms show up (Mild blood pressure indicates blood pressures ranging from 140 to 159 mmHg systolic and/or 90 to 99 mmHg diastolic). However, cumulative evidences prove that microvascular rarefaction exist in hypertensive patients with even primary hypertension stage 1. Exercise prescription is gathering great importance in preventive health. Aerobic exercise, especially, has the potential to diminish blood pressure values, and aerobic exercise can promote angiogenesis in coronary heart disease. Notch signaling plays an important role in vascular formation and maintenance. However, there is no prospective, randomized, controlled, clinic trial to investigate the effect of exercise on microcirculation rarefaction in hypertension. In summary, investigators propose a hypothesis that aerobic exercise might not only have a blood pressure lowing effect but also improve microcirculation rarefaction in Chinese male adults with primary mild hypertension. For that, subjects will be enrolled for one pre-intervention cardiopulmonary exercise test (CPET) and then randomized in aerobic exercise intervention group and control group (only health education), the intervention will be carried out by Cycle Ergometer, the protocol consists of 3 sessions a day: 3 minutes Warm up, 45 minutes Resistance Exercise at 75% of HRmax; 10 minutes Recovery. Thus 58 minutes a day and 5 days a week (about 2000kcal) and 12 weeks in total. Prior and after all intervention sessions (12 weeks), nail fold capillary microscopy and retinal capillary Optical Coherence Tomography(OCT) angiography will be assessed, as well as 24h blood pressure monitoring, echocardiography, forearm blood flow and reactive hyperemia by venous occlusion plethysmography (FMD), PWV, central arterial pressure, RHI with Endopat, also the quantification of endothelial progenistor cells(EPCs) separated from peripheral blood.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | July 30, 2017 |
Est. primary completion date | July 30, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 25 Years to 40 Years |
Eligibility |
Inclusion Criteria: - Subjects range from 18 to 40 years old. - male - Blood pressure is primary hypertension stage I(systolic blood pressure 140 to 159 mmHg and/or diastolic blood pressure 90 to 99 mmHg). - Able to participate in exercise - No regular physically active in the last 4 months - Provide informed consent and willingness to cooperate with the study protocol Exclusion Criteria: - Less than 18 years old or above 40 years old - Secondary hypertension. - Females - Systemic diseases such as diabetes, HIV/AIDS, liver disease, chronic renal failure, tuberculosis, and autoimmune diseases - Medical history of cardiovascular disease: acute myocardial infarct, stable angina, unstable angina, heart failure, atrial fibrillation, atrioventricular blockade, peripheral vascular disease or cerebrovascular accident - Patients who are unfavorable of long-term follow-up or poor compliance |
Country | Name | City | State |
---|---|---|---|
China | First Affiliated Hospital,Sun Yat-sen University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital, Sun Yat-Sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Retinal capillary density with Quantitative Optical Coherence Tomography(OCT) angiography(OCT)) | Change from Baseline retinal capillary density at 12 weeks | ||
Primary | Nail fold capillary numbers per square millimeter( /mm²) | Change from Baseline nail fold capillary density at 12 weeks | ||
Secondary | 24 hours ambulatory blood pressure (ABP) in millimeters of mercury(mmHg) | Change from Baseline Systolic Blood Pressure and Diastolic Blood Pressure at 12 weeks | ||
Secondary | Flow-mediated Dilation(FMD) in % | The percentage change in brachial artery diameter from baseline | Change from Baseline percentage at 12 weeks | |
Secondary | Reactive Hyperemia Index(RHI) in the ratio of the average amplitude of the PAT signal | RHI was measured using the RH-PAT system (EndoPAT):A blood pressure cuff was placed on 1 upper arm with the contralateral arm serving as a control. A PAT probe was placed on 1 finger of each hand. After a 5-minute equilibration period, the cuff was inflated to 60 mm Hg above the systolic pressure or to 200 mm Hg for 5 minutes, then deflated to induce reactive hyperemia. | Change from Baseline ratio at 12 weeks | |
Secondary | Abilities of tube formation of endothelial progenistor cells(EPCs) in tube numbers | Tube formation ability of EPCs was evaluated by counting tube numbers. Images of tube morphology were taken under the inverted phase contrast microscope. | Change from Baseline tube numbers at 12 weeks | |
Secondary | Left Ventricular End-diastolic Volume (LVEDV) in milliliter(ml) | Change from Baseline volume at 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00573742 -
Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients
|
N/A | |
Recruiting |
NCT06208072 -
The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.
|
N/A | |
Recruiting |
NCT06049862 -
The Effectiveness of "MaRiTensi" in Increasing Self-Care and Blood Pressure Control: Randomized Controlled Trial
|
N/A | |
Completed |
NCT00819104 -
A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components
|
Phase 4 | |
Not yet recruiting |
NCT06091176 -
Assessment of Efficacy and Safety of Amicomed®, for the Management of Essential Hypertension
|
N/A | |
Recruiting |
NCT01742702 -
HaemoDYNAMICs in Primary and Secondary Hypertension
|
||
Completed |
NCT00794885 -
China Stroke Primary Prevention Trial
|
Phase 4 | |
Active, not recruiting |
NCT04381520 -
Heat-sensitive Moxibustion Self-administration in Patients in the Community With Primary Hypertension: Protocol for a Multi-center, Pragmatic, Non-randomized Trial
|
N/A | |
Completed |
NCT00865501 -
Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease
|
Phase 3 | |
Active, not recruiting |
NCT04788563 -
A Randomized Patient Preference Trial on Heat-sensitive Moxibustion for Primary Hypertension in Community
|
N/A | |
Completed |
NCT02184858 -
Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension
|
Phase 4 | |
Completed |
NCT03105687 -
Effectiveness of SMS Reminders of Blood Pressure-lowering Drugs Intake
|
N/A | |
Completed |
NCT01392534 -
Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting
|
N/A | |
Active, not recruiting |
NCT03015311 -
Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients
|
N/A | |
Enrolling by invitation |
NCT03470974 -
The Effect of Self-Titration and Predictors for Blood Pressure Control in Patients With Hypertension
|
N/A | |
Active, not recruiting |
NCT01844570 -
Levamlodipine Maleate or Amlodipine Besylate for Treatment of Hypertension: A Comparative Effectiveness Research
|
N/A | |
Completed |
NCT01241487 -
A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy
|
Phase 4 | |
Completed |
NCT00882947 -
Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
|
Phase 4 | |
Active, not recruiting |
NCT03310684 -
Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)
|
||
Not yet recruiting |
NCT02901704 -
Renal Denervation by Iberis MultiElectrode Renal Denervation System in Patients With Primary Hypertension
|
Phase 3 |